FairJourney Bio (“FJBio”), a global antibody discovery expert, has announced the program for The Antibody Series (TAS) 2026, which will explore how insights from natural antibody repertoires, advances in computational design, and novel engineering strategies are transforming the discovery and development of antibody therapeutics.
